Ras in cancer and developmental diseases

Genes and Cancer

Volumn 2, Issue 3, 2011, Pages 344-358

  Fernández Medarde, Alberto ^a   Santos, Eugenio ^a  

^a Centro de Investigacion del Cancer   (Spain)

Author keywords

Cancer; Developmental syndromes; Mutation; Oncogenes; Ras; Ras MAPK pathway

Indexed keywords

AS 703026; CANCER VACCINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GSK 1120212; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RADIOACTIVE IODINE; RAS PROTEIN; RIBOZYME; ROMIDEPSIN; SORAFENIB; TIPIFARNIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER IMMUNIZATION; CAPILLARY MALFORMATION ARTERIOVENOUS MALFORMATION; CARCINOGENESIS; CARDIOFACIOCUTANEOUS SYNDROME; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLORECTAL CARCINOMA; CONGENITAL BLOOD VESSEL MALFORMATION; CONGENITAL HEART MALFORMATION; DEVELOPMENTAL DISORDER; DRUG RESPONSE; DRUG TARGETING; FACE MALFORMATION; GENETIC DISORDER; GINGIVA FIBROMATOSIS; HEMATOLOGIC MALIGNANCY; HUMAN; LEGIUS SYNDROME; LEOPARD SYNDROME; LIVER CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE MYELOMA; NEUROFIBROMATOSIS; NONHUMAN; NOONAN SYNDROME; ONCOCYTOMA; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SEMINOMA; SIGNAL TRANSDUCTION; SKIN MALFORMATION; SOMATIC MUTATION; THYROID CARCINOMA; UNSPECIFIED SIDE EFFECT;

EID: 79960052850     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911411084     Document Type: Review

References (187)

1. Rajalingam K, Schreck R, Rapp UR, Albert S. Ras oncogenes and their downstream targets. Biochim Biophys Acta. 2007;1773(8):1177-95.
2. Stites EC, Ravichandran KS. A systems perspective of ras signaling in cancer. Clin Cancer Res. 2009;15(5):1510-3.
3. Der CJ, Krontiris TG, Cooper GM. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci U S A. 1982;79(11):3637-40.
4. Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature.1982;297(5866):474-8.
5. Santos E, Tronick SR, Aaronson SA, Pulciani S, Barbacid M. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature. 1982;298(5872):343-7.
6. Cacev T, Radosevic S, Spaventi R, Pavelic K, Kapitanovic S. NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer. Gut. 2005;54(8):1129-35.
7. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev.2007;17(1):31-9.
8. Khoukaz T. Administration of anti-EGFR therapy: a practical review. Semin Oncol Nurs.2006;22(1 Suppl 1):20-7.
9. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54.
10. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-34.
11. Marchuk DA, Saulino AM, Tavakkol R, et al. Cdna cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics. 1991;11(4):931-40.
12. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29(4):465-8.
13. Denayer E, de Ravel T, Legius E. Clinical and molecular aspects of RAS related disorders. J Med Genet. 2008;45(11):695-703.
14. Tidyman WE, Rauen KA. The rasopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev. 2009;19(3):230-6.
15. Kanwar M, Kowluru RA. Diabetes regulates small molecular weight G-protein, H-Ras, in the microvasculature of the retina: implication in the development of retinopathy. Microvasc Res. 2008;76(3):189-93.
16. Rapoport MJ, Weiss L, Mor A, et al. Prevention of autoimmune diabetes by linomide in nonobese diabetic (NOD) mice is associated with up-regulation of the TCR-mediated activation of p21(ras). J Immunol. 1996;157(10):4721-5.
17. Benter IF, Yousif MH, Canatan H, Akhtar S. Inhibition of Ca2+/calmodulin-dependent protein kinase II, RAS-gtpase and 20-hydroxyeicosatetraenoic acid attenuates the development of diabetes-induced vascular dysfunction in the rat carotid artery. Pharmacol Res. 2005;52(3):252-7.
18. Yousif MH. Signal transduction through Ras- GTPase and Ca2+/calmodulin-dependent protein kinase II contributes to development of diabetesinduced renal vascular dysfunction. Cell Biochem Funct. 2006;24(4):299-305.
19. Draznin B, Miles P, Kruszynska Y, et al. Effects of insulin on prenylation as a mechanism of potentially detrimental influence of hyperinsulinemia. Endocrinology. 2000;141(4):1310-6.
20. Kocher HM, Moorhead J, Sharpe CC, et al. Expression of Ras GTPases in normal kidney and in glomerulonephritis. Nephrol Dial Transplant 2003;18(11):2284-92.
21. Luth HJ, Holzer M, Gertz HJ, Arendt T. Aberrant expression of nNOS in pyramidal neurons in Alzheimer's disease is highly co-localized with p21ras and p16ink4a. Brain Res. 2000;852(1): 45-55.
22. Raymond FL, Tarpey PS, Edkins S, et al. Mutations in ZDHHC9, which encodes a palmitoyltransferase of NRAS and HRAS, cause X-linked mental retardation associated with a Marfanoid habitus. Am J Hum Genet. 2007;80(5):982-7.
23. Confino-Cohen R, Aharoni D, Goldberg A, et al. Evidence for aberrant regulation of the p21Ras pathway in PBMCs of patients with chronic idiopathic urticaria. J Allergy Clin Immunol. 2002;109(2):349-56.
24. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(Database issue):D945-50.
25. Shimizu N, Ohtsubo M, Minoshima S. Mutation- View/KMcancerDB: a database for cancer gene mutations. Cancer Sci. 2007;98(3):259-67.
26. Esteban LM, Vicario-Abejon C, Fernandez- Salguero P, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mo use growth and development. Mol Cell Biol. 2001;21(5):1444-52.
27. Johnson L, Greenbaum D, Cichowski K, et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 1997;11(19):2468-81.
28. Janakiraman M, Vakiani E, Zeng Z, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 2010;70(14):5901-11.
29. Naguib A, Wilson CH, Adams DJ, Arends MJ. Activation of K-RAS by co-mutation of codons 19 and 20 is transforming. J Mol Signal. 2011;6:2.
30. Pulciani S, Santos E, Long LK, Sorrentino V, Barbacid M. Ras Gene amplification and malignant transformation. Mol Cell Biol. 1985;5(10):2836-41.
31. Heighway J, Hasleton PS. C-Ki-ras amplification in human lung cancer. Br J Cancer. 1986;53(2):285-7.
32. Taya Y, Hosogai K, Hirohashi S, et al. A novel combination of K-ras and myc amplification accompanied by point mutational activation of K-ras in a human lung cancer. EMBO J. 1984;3(12):2943-6.
33. Graham KA, Richardson CL, Minden MD, Trent JM, Buick RN. Varying degrees of amplification of the N-ras oncogene in the human breast cancer cell line MCF-7. Cancer Res. 1985;45(5):2201-5.
34. Akkiprik M, Celikel CA, Dusunceli F, et al. Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients. Turk J Gastroenterol. 2008;19(1):22-7.
35. Wang Q, Chaerkady R, Wu J, et al. Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A. 2011.
36. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53(4):549-54.
37. Kipp BR, Fritcher EG, Clayton AC, et al. Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn. 2010;12(6):780-6.
38. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20(10):1218-49.
39. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 1994;54(13):3568-73.
40. Dergham ST, Dugan MC, Kucway R, et al. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol. 1997;21(2):127-43.
41. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas: a study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allelespecific oligonucleotide hybridization. Am J Pathol. 1993;143(2):545-54.
42. Chen H, Tu H, Meng ZQ, et al. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol. 2010;36(7):657-62.
43. Kim J, Reber HA, Dry SM, et al. Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut. 2006;55(11):1598-605.
44. Immervoll H, Hoem D, Kugarajh K, Steine SJ, Molven A. Molecular analysis of the EGFRRAS- RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch. 2006;448(6): 788-96.
45. Kawesha A, Ghaneh P, Andren-Sandberg A, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbb-2 and erbb-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer. 2000;89(6):469-74.
46. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001;93(14):1062-74.
47. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61(1):131-7.
48. Kohl NE, Wilson FR, Mosser SD, et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A. 1994;91(19):9141-5.
49. Cohen SJ, Ho L, Ranganathan S, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003;21(7):1301-6.
50. Martin NE, Brunner TB, Kiel KD, et al. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res. 2004;10(16):5447-54.
51. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22(8):1430-8.
52. Whyte DB, Kirschmeier P, Hockenberry TN, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997;272(22):14459-64.
53. Weden S, Klemp M, Gladhaug IP, et al. Longterm follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer. 2011;128(5):1120-8.
54. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011;50(5):307-12.
55. Irahara N, Baba Y, Nosho K, et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol. 2010;19(3):157-63.
56. McLellan EA, Owen RA, Stepniewska KA, Sheffield JP, Lemoine NR. High frequency of K-ras mutations in sporadic colorectal adenomas. Gut. 1993;34(3):392-6.
57. Nash GM, Gimbel M, Cohen AM, et al. KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol. 2010;17(2):416-24.
58. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002;62(22):6451-5.
59. Pretlow TP, Pretlow TG. Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer? Biochim Biophys Acta. 2005;1756(2): 83-96.
60. Andersen SN, Lovig T, Breivik J, et al. K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol. 1997;32(1):62-9.
61. Chang YS, Yeh KT, Chang TJ, et al. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer. 2009;9:179.
62. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54(9):1283-6.
63. Zavodna K, Konecny M, Krivulcik T, et al. Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients. Neoplasm. 2009;56(3):275-8.
64. Cejas P, Lopez-Gomez M, Aguayo C, et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. Plos One. 2009;4(12):e8199.
65. Nash GM, Gimbel M, Shia J, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010;17(2):572-8.
66. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374-9.
67. Raponi M, Winkler H, Dracopoli NC. KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol. 2008;8(4):413-8.
68. Saif MW, Oettle H, Vervenne WL, et al. Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J. 2009;15(4):339-43.
69. Deschoolmeester V, Boeckx C. Baay M. et al. KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br J Cancer. 2010;103(10):1627-36.
70. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol. 1999;17(2):668-75.
71. Nelson MA, Wymer J, Clements N Jr. Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers. Cancer Lett. 1996;103(1):115-21.
72. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene. 1990;5(7):1037-43.
73. Garassino MC, Marabese M, Rusconi P, et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in nonsmall- cell lung cancer. Ann Oncol. 2011;22(1):235-7.
74. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001;92(6):1525-30.
75. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008;14(18):5731-4.
76. Singh M, Lima A, Molina R, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol. 2010;28(6):585-93.
77. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001;410(6832):1111-6.
78. Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci.2004;95(3):197-204.
79. DeMarini DM, Landi S, Tian D, et al. Lung tumor KRAS and TP53 mutations in nonsmokers reflect exposure to PAH-rich coal combustion emissions. Cancer Res. 2001;61(18):6679-81.
80. Husgafvel-Pursiainen K, Hackman P, Ridanpaa M, et al. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int J Cancer. 1993;53(2):250-6.
81. Rodenhuis S, Slebos RJ, Boot AJ, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1988;48(20):5738-41.
82. Gautschi O, Huegli B, Ziegler A, et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett. 2007;254(2):265-73.
83. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005;92(1):131-9.
84. Sasaki H, Okuda K, Kawano O, et al. Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using lightcycler. Oncol Rep. 2007;18(3):623-8.
85. Camps C, Sirera R, Bremnes R, et al. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer. 2005;50(3):339-46.
86. Lu C, Soria JC, Tang X, et al. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol. 2004;22(22):4575-83.
87. Ramirez JL, Sarries C, de Castro PL, et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett. 2003;193(2):207-16.
88. Keohavong P, demichele MA, Melacrinos AC, et al. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res. 1996;2(2):411-8.
89. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23(25):5900-9.
90. Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat. 2007;28 (6):578-88.
91. Omholt K, Karsberg S, Platz A, et al. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res. 2002;8(11):3468-74.
92. Van der Lubbe JL, Rosdorff HJ, Bos JL, Van der Eb AJ. Activation of N-ras induced by ultraviolet irradiation in vitro. Oncogene Res. 1988;3(1): 9-20.
93. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62(23):6997-7000.
94. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95(6):484-6.
95. Ugurel S, Thirumaran RK, Bloethner S, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. Plos One. 2007;2(2):e236.
96. van Elsas A, Scheibenbogen C, van der Minne C, et al. UV-induced N-ras mutations are T-cell targets in human melanoma. Melanoma Res. 1997;7(Suppl 2):S107-13.
97. Demunter A, Ahmadian MR, Libbrecht L, et al. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res. 2001;61(12):4916-22.
98. Gajewski TF, Niedzwiecki D, Johnson J, et al. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104. In: Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post- Meeting Edition), Vol 24, No 18S(June 20 Supplement). 2006; p. 8014.
99. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765-81.
100. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol. 2010;28(4):401-8.
101. Boulalas I, Zaravinos A, Karyotis I, Delakas D, Spandidos DA. Activation of RAS family genes in urothelial carcinoma. J Urol. 2009;181(5):2312-9.
102. Johne A, Roots I, Brockmoller J. A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(1):68-70.
103. Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol.2010;28(4):409-28.
104. Irie A, Kashani-Sabet M, Scanlon KJ, Uchida T, Baba S. Hammerhead ribozymes as therapeutic agents for bladder cancer. Mol Urol. 2000;4(2):61-6.
105. Watanabe T, Shinohara N, Sazawa A, et al. Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant. Int J Cancer. 2001;92(5):712-7.
106. Choudhary S, Wang HC. Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells. Mol Cancer Ther. 2007;6(3):1099-111.
107. Garcia-Rostan G, Zhao H, Camp RL, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;21(17):3226-35.
108. Greco A, Borrello MG, Miranda C, Degl'Innocenti D, Pierotti MA. Molecularpathology of differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2009;53(5):440-53.
109. Wells SA Jr, Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res. 2009;15(23):7119-23.
110. Hara H, Fulton N, Yashiro T, et al. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery. 1994;116(6):1010-6.
111. Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw. 2010;8(11):1277-86; quiz 1287.
112. Duntas LH, Bernardini R. Sorafenib: rays of hope in thyroid cancer. Thyroid. 2010;20(12):1351-8.
113. Hong DS, Sebti SM, Newman RA, et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009;15(22):7061-8.
114. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood. 2000;96(5):1655-69.
115. Steinbrunn T, Stuhmer T, Gattenlohner S, et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood. 2011;117(6):1998-2004.
116. MacKenzie KL, Dolnikov A, Millington M, Shounan Y, Symonds G. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood. 1999;93(6):2043-56.
117. Reilly JT. Receptor tyrosine kinases in normal and malignant haematopoiesis. Blood Rev. 2003;17(4):241-8.
118. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. 1994;330(9):597-601.
119. Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood eukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer. 1994;70(5):969-72.
120. Zou X, Calame K. Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. J Biol Chem. 1999;274(26):18141-4.
121. Paulsson K, Horvat A, Strombeck B, et al. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2008;47(1):26-33.
122. De Melo MB, Lorand-Metze I, Lima CS, Saad ST, Costa FF. N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis. Leuk Lymphoma. 1997;24(3-4):309-17.
123. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93(9):3074-80.
124. Shih LY, Huang CF, Wang PN, et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia. 2004;18(3):466-75.
125. Coghlan DW, Morley AA, Matthews JP, Bishop JF. The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia. Leukemia. 1994;8(10):1682-7.
126. Lubbert M, Mirro J Jr, Miller CW, et al. N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood. 1990;75(5):1163-9.
127. Perentesis JP, Bhatia S, Boyle E, et al. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia. 2004;18(4):685-92.
128. Paquette RL, Landaw EM, Pierre RV, et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood. 1993;82(2):590-9.
129. Chng WJ, Gonzalez-Paz N, Price-Troska T, et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia. 2008;22(12):2280-2284.
130. Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist. 2005;10(8):565-78.
131. Mazieres J, Pradines A, Favre G. Perspectives on farnesyl transferase inhibitors in cancer therapy. Cancer Lett. 2004;206(2):159-67.
132. Braun T, Fenaux P. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2008;141(5):576-86.
133. Mori S, Cortes J, Kantarjian H, et al. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma. 2008;49(12):2246-55.
134. Goldman JM. Chronic myeloid leukemia: a historical perspective. Semin Hematol. 2010;47(4):302-11.
135. Marin D. Current status of imatinib as frontline therapy for chronic myeloid leukemia. Semin Hematol. 2010;47(4):312-8.
136. Schondorf T, Rutzel S, Andrack A, et al. Immunohistochemical analysis reveals a protective effect of H-ras expression mediated via apoptosis in node-negative breast cancer patients. Int J Oncol. 2002;20(2):273-7.
137. Watson DM, Elton RA, Jack WJ, et al. The H-ras oncogene product p21 and prognosis in human breast cancer. Breast Cancer Res Treat. 1991;17(3):161-9.
138. Calvisi DF, Ladu S, Conner EA, et al. Inactivation of Ras gtpase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol. 2011;54(2):311-9.
139. Kitanaka C, Kato K, Ijiri R, et al. Increased Ras expression and caspase-independent neuroblastoma cell death: possible mechanism of spontaneous neuroblastoma regression. J Natl Cancer Inst. 2002;94(5):358-68.
140. Leung TW, Cheung AN, Cheng DK, Wong LC, Ngan HY. Expressions of c-erbb-2, epidermal growth factor receptor and pan-ras protooncogenes in adenocarcinoma of the cervix: correlation with clinical prognosis. Oncol Rep. 2001;8(5):1159-64.
141. Mammas IN, Zafiropoulos A, Koumantakis E, Sifakis S, Spandidos DA. Transcriptional activation of H- and N-ras oncogenes in human cervical cancer. Gynecol Oncol. 2004;92(3):941-8.
142. Lam EK, Wang X, Shin VY, et al. A microRNA contribution to aberrant Ras activation in gastric cancer. Am J Transl Res. 2011;3(2):209-18.
143. Coutinho CM, Bassini AS, Gutierrez LG, et al. Genetic alterations in Ki-ras and Ha-ras genes in juvenile nasopharyngeal angiofibromas and head and neck cancer. Sao Paulo Med J. 1999;117(3):113-20.
144. Sathyan KM, Nalinakumari KR, Kannan S. H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma. Mod Pathol. 2007;20(11):1141-8.
145. Kiaris H, Spandidos DA, Jones AS, Vaughan ED, Field JK. Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br J Cancer. 1995;72(1):123-8.
146. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7(4):295-308.
147. Schubbert S, Bollag G, Shannon K. Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev. 2007;17(1):15-22.
148. Schubbert S, Zenker M, Rowe SL, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet. 2006;38(3):331-6.
149. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol. 2010;1(1):2-26.
150. Tidyman WE, Rauen KA. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev Mol Med. 2008;10:e37.
151. Cawthon RM, O'Connell P, Buchberg AM, et al. Identification and characterization of transcripts from the neurofibromatosis 1 region: the sequence and genomic structure of EVI2 and mapping of other transcripts. Genomics. 1990;7(4):555-65.
152. Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med. 2010;12(1):1-11.
153. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol. 2007;6(4):340-51.
154. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist. 2000;5(6):477-85.
155. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12(2):144-8.
156. Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol. 2000;151(1):33-40.
157. Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis. 2008;3:13.
158. Matozaki T, Murata Y, Saito Y, Okazawa H, Ohnishi H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 2009;100(10): 1786-93.
159. Oishi K, Zhang H, Gault WJ, et al. Phosphatase- defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development. Hum Mol Genet. 2009;18(1):193-201.
160. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem.2006;281(10):6785-92.
161. Cirstea IC, Kutsche K, Dvorsky R, et al. A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet. 2010;42(1): 27-9.
162. Cordeddu V, Di Schiavi E, Pennacchio LA, et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonanlike syndrome with loose anagen hair. Nat Genet. 2009;41(9):1022-6.
163. Nava C, Hanna N, Michot C, et al. Cardiofacio- cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet.2007;44(12):763-71.
164. Pandit B, Sarkozy A, Pennacchio LA, et al. Gainof- function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39(8):1007-12.
165. Razzaque MA, Nishizawa T, Komoike Y, et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet.2007;39(8):1013-7.
166. Roberts AE, Araki T, Swanson KD, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet. 2007;39(1):70-4.
167. Gremer L, Merbitz-Zahradnik T, Dvorsky R, et al. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat.2010;32(1):33-43.
168. Jorge AA, Malaquias AC, Arnhold IJ, Mendonca BB. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway. Horm Res. 2009;71(4):185-93.
169. Wu X, Simpson J, Hong JH, et al. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest. 2011;121(3):1009-25.
170. Brems H, Chmara M, Sahbatou M, et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet. 2007;39(9):1120-6.
171. Denayer E, Chmara M, Brems H, et al. Legius syndrome in fourteen families. Hum Mutat.2011;32(1):E1985-98.
172. Aoki Y, Niihori T, Kawame H, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet.2005;37(10):1038-40.
173. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat. 2008;29(8):992-1006.
174. Chen X, Mitsutake N, LaPerle K, et al. Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci U S A. 2009;106(19):7979-84.
175. Schuhmacher AJ, Guerra C, Sauzeau V, et al. A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest. 2008;118(6):2169-79.
176. Niihori T, Aoki Y, Narumi Y, et al. Germline KRAS and BRAF mutations in cardiofacio- cutaneous syndrome. Nat Genet. 2006; 38(3):294-6.
177. Rodriguez-Viciana P, Tetsu O, Tidyman WE, et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science. 2006;311(5765):1287-90.
178. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209-21.
179. Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008;68(12):4853-61.
180. Hart TC, Zhang Y, Gorry MC, et al. A mutation in the SOS1 gene causes hereditary gingival fibromatosis type 1. Am J Hum Genet.2002;70(4):943-54.
181. Jang SI, Lee EJ, Hart PS, et al. Germ line gain of function with SOS1 mutation in hereditary gingival fibromatosis. J Biol Chem.2007;282(28):20245-55.
182. Oliveira JB, Bidere N, Niemela JE, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 2007;104(21):8953-8.
183. Eerola I, Boon LM, Mulliken JB, et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet. 2003; 73(6):1240-9.
184. Revencu N, Boon LM, Mulliken JB, et al. Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Hum Mutat. 2008;29(7):959-65.
185. Shen MH, Harper PS, Upadhyaya M. Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet. 1996;33(1):2-17.
186. Jim HP, Upadhyaya M. Novel human pathological mutations. Gene symbol: SPRED1. Disease: Legius syndrome. Hum Genet.2010;127(1):111-2.
187. Hershkovitz D, Bercovich D, Sprecher E, Lapidot M. RASA1 mutations may cause hereditary capillary malformations without arteriovenous malformations. Br J Dermatol. 2008;158(5):1035-40